Evidence map›Paper›PMID 36232786›Full record

ArticleInternational journal of molecular sciences2022

A New Structural Model of Apolipoprotein B100 Based on Computational Modeling and Cross Linking.

Kianoush Jeiran, Scott M Gordon, Denis O Sviridov, Angel M Aponte, Amanda Haymond, Grzegorz Piszczek, Diego Lucero, Edward B Neufeld, Iosif I Vaisman, Lance Liotta and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. State-of-the-Art and Future Directions in Structural Proteomics.Molecular & cellular proteomics : MCP · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kianoush JeiranLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Scott M GordonDepartment of Physiology and Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY 40536, USA.
Denis O SviridovLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Angel M AponteProteomics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Amanda HaymondCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Grzegorz PiszczekBiophysics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-5270-3678
Diego LuceroLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-2833-5681
Edward B NeufeldLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-1248-6613
Iosif I VaismanSchool of Systems Biology, George Mason University, Manassas, VA 20110, USA.ORCID 0000-0001-6858-1516
Lance LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA.
Ancha BaranovaSchool of Systems Biology, George Mason University, Manassas, VA 20110, USA.
Alan T RemaleyLipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Funding

National Heart Lung and Blood Institute HL006095-13
6 · The paper itself

Abstract

ApoB-100 is a member of a large lipid transfer protein superfamily and is one of the main apolipoproteins found on low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particles. Despite its clinical significance for the development of cardiovascular disease, there is limited information on apoB-100 structure. We have developed a novel method based on the "divide and conquer" algorithm, using PSIPRED software, by dividing apoB-100 into five subunits and 11 domains. Models of each domain were prepared using I-TASSER, DEMO, RoseTTAFold, Phyre2, and MODELLER. Subsequently, we used disuccinimidyl sulfoxide (DSSO), a new mass spectrometry cleavable cross-linker, and the known position of disulfide bonds to experimentally validate each model. We obtained 65 unique DSSO cross-links, of which 87.5% were within a 26 Å threshold in the final model. We also evaluated the positions of cysteine residues involved in the eight known disulfide bonds in apoB-100, and each pair was measured within the expected 5.6 Å constraint. Finally, multiple domains were combined by applying constraints based on detected long-range DSSO cross-links to generate five subunits, which were subsequently merged to achieve an uninterrupted architecture for apoB-100 around a lipoprotein particle. Moreover, the dynamics of apoB-100 during particle size transitions was examined by comparing VLDL and LDL computational models and using experimental cross-linking data. In addition, the proposed model of receptor ligand binding of apoB-100 provides new insights into some of its functions.

Indexed as

Apolipoproteins BCysteineApolipoprotein B-100Computer SimulationDisulfidesLigandsLipoproteins, LDLLipoproteins, VLDLModels, StructuralSulfoxidesApolipoprotein B-100Apolipoproteins BCysteineDisulfidesLigandsLipoproteins, LDLLipoproteins, VLDLSulfoxidesapolipoprotein B100cardiovascular diseasedivide and conquer algorithmDSSO cross-linkerhomology modelingITASSERLDL receptor ligandlipovitellinvery low-density lipoprotein

Identifiers

PMID36232786
PMCPMC9569473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.